Antibody molecules to dengue virus and uses thereof
AssigneeVisterra, Inc.
InventorsLuke Robinson, Zachary Shriver, James R. Myette, Gregory Babcock, Karthik Viswanathan
Life of this patent
Estimating the term…
Abstract
Antibody molecules that specifically bind to dengue virus are disclosed. In certain embodiments, the antibody molecule bind to dengue virus serotypes DV-1, DV-2, DV-3, and DV-4. The antibody molecules can be used to treat, prevent, and/or diagnose dengue virus.
Claims25
An isolated antibody molecule capable of binding dengue virus, comprising:
- (a) a heavy chain immunoglobulin variable region segment comprising:
- a CDR1 comprising the sequence DVYMS (SEQ ID NO:
- 3),
- a CDR2 comprising the sequence RIDPENGDTKYDPKLQG (SEQ ID NO:
- 4), and
- a CDR3 comprising the sequence GWEGFAY (SEQ ID NO:
- 5);
- and
- (b) a light chain variable region segment comprising:
- a CDR1 comprising the sequence RASENVDKYGNSFMH (SEQ ID NO:
- 6),
- a CDR2 comprising the sequence RASELQW (SEQ ID NO:
- 7), and
- a CDR3 comprising the sequence QRSNEVPWT (SEQ ID NO:
- 8).
3-4. (canceled)
(canceled)
(canceled)
14-18. (canceled)
A nucleic acid encoding the antibody heavy or light chain variable region of an antibody molecule capable of binding dengue virus, wherein the antibody molecule comprises:
- (a) a heavy chain immunoglobulin variable region segment comprising:
- a CDR1 comprising the sequence DVYMS (SEQ ID NO:
- 3),
- a CDR2 comprising the sequence RIDPENGDTKYDPKLQG (SEQ ID NO:
- 4), and
- a CDR3 comprising the sequence GWEGFAY (SEQ ID NO:
- 5);
- and
- (b) a light chain variable region segment comprising:
- a CDR1 comprising the sequence RASENVDKYGNSFMH (SEQ ID NO:
- 6),
- a CDR2 comprising the sequence RASELQW (SEQ ID NO:
- 7), and
- a CDR3 comprising the sequence QRSNEVPWT (SEQ ID NO:
- 8).
A method of producing an antibody molecule or fragment thereof, comprising culturing a host cell under conditions suitable for gene expression, wherein the host cell comprises a nucleic acid encoding the antibody heavy or light chain variable region of an antibody molecule capable of binding dengue virus, wherein the antibody molecule comprises:
- (a) a heavy chain immunoglobulin variable region segment comprising:
- a CDR1 comprising the sequence DVYMS (SEQ ID NO:
- 3),
- a CDR2 comprising the sequence RIDPENGDTKYDPKLQG (SEQ ID NO:
- 4), and
- a CDR3 comprising the sequence GWEGFAY (SEQ ID NO:
- 5);
- and
- (b) a light chain variable region segment comprising:
- a CDR1 comprising the sequence RASENVDKYGNSFMH (SEQ ID NO:
- 6),
- a CDR2 comprising the sequence RASELQW (SEQ ID NO:
- 7), and
- a CDR3 comprising the sequence QRSNEVPWT (SEQ ID NO:
- 8).
A method of treating dengue virus, comprising administering to a subject in need thereof an isolated antibody molecule in an amount effective to treat the virus, wherein the antibody molecule comprises:
- (a) a heavy chain immunoglobulin variable region segment comprising:
- a CDR1 comprising the sequence DVYMS (SEQ ID NO:
- 3),
- a CDR2 comprising the sequence RIDPENGDTKYDPKLQG (SEQ ID NO:
- 4), and
- a CDR3 comprising the sequence GWEGFAY (SEQ ID NO:
- 5);
- and
- (b) a light chain variable region segment comprising:
- a CDR1 comprising the sequence RASENVDKYGNSFMH (SEQ ID NO:
- 6),
- a CDR2 comprising the sequence RASELQW (SEQ ID NO:
- 7), and
- a CDR3 comprising the sequence QRSNEVPWT (SEQ ID NO:
- 8).
Dependencies are inferred from the claim text.